UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000033381
Receipt No. R000038003
Scientific Title A clinical trial for 8 continuous weeks intake of HK1502 that are solid preparations blended with vitamin.
Date of disclosure of the study information 2019/08/01
Last modified on 2019/09/10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A clinical trial for 8 continuous weeks intake of HK1502 that are solid preparations blended with vitamin.
Acronym A clinical trial for 8 continuous weeks intake of HK1502.
Scientific Title A clinical trial for 8 continuous weeks intake of HK1502 that are solid preparations blended with vitamin.
Scientific Title:Acronym A clinical trial for 8 continuous weeks intake of HK1502.
Region
Japan

Condition
Condition Not applicable
Classification by specialty
Not applicable
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate efficacy and safety of HK1502 that are solid preparations blended with vitamin on 8 continuous weeks intake in japanese healthy adult male and female.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes *Skin AGE fluorometry
*Doctor's findings such as subjective or objective symptoms and medical observations after the clinical trial start

Key secondary outcomes *Questionnaire survey(five-point scale)
*Physical examinations such as height, body weight, blood pressure and others
*Subject diary(doctor's findings such as expression presence or absence of adverse events)


Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification NO
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Prevention
Type of intervention
Other
Interventions/Control_1 Each subjects consumed HK1502 that are solid preparations blended with vitamin for 8 continuous weeks.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
35 years-old <=
Age-upper limit
65 years-old >=
Gender Male and Female
Key inclusion criteria 1)Subjects(japanese male and female) who are able to show their willingness of participating to the clinical trial, and who are able to obtain written consent to participate in the clinical trial after understanding explanation of the clinical trial.
2)Subjects who aged 35 years-old to 65 years-old.
3)BMI 18.5 more.
4)Subjects who are not regularly consuming supplements that are some possibility of having a negative influence on the clinical trial, or who are able to stop the supplements from two weeks before the clinical trial start to the end of the clinical trial.
5)The right hand is dominant hand.
Key exclusion criteria 1)Subjects who suffer any disease at present and who are going to take continuous medical treatments during the clinical trial, or who are going to use the over-the-counter drug.
2)Subjects who have trauma on the middle fingertip of the left hand, and who have a negative influence on the skin AGE fluorometry.
3)Subjects who have hypersensitivity or allergic reaction to a certain drug medicine or food.
4)Subjects who have an operation career such as hepatectomy, gastrectomy, gastrointestinal suturesin, intestinal resection, transplanting and others in a digestive organ.
5)Subjects who have impaired respiratory and cardiovascular organ.
6)Subjects with experience of alcoholism, or who drink liquor excessively(pure alcohol conversion : over-60g per day).
7)Subjects who have participated in other clinical trials and use tests that apply foods and others within the last 12 weeks prior to the current clinical trial.
8)Subjects who apply to the following.
(1)Male subjects who donated 400ml of blood within the last 12 weeks prior to the current clinical trial.
In female, within the last 16 weeks.
(2)Subjects who donated 200ml of blood within the last 4 weeks prior to the current clinical trial.
(3)Subjects who donated components of blood such as blood platelet and blood plasma within the last 2 weeks prior to the current clinical trial.
(4)Subjects who have had experiences of a blood collecting conforming to the above matters.
9)Subjects who are the pregnant or breast-feeding woman.
10)Subjects who are planning to become the pregnant woman during the clinical trial.
11)Others who have been determined ineligible or undesirable by investigator.
Target sample size 23

Research contact person
Name of lead principal investigator
1st name Tomohiko
Middle name
Last name Yamaguchi
Organization DAIICHI SANKYO HEALTHCARE CO., LTD.
Division name R&D Department
Zip code 103-8234
Address 3-14-10 Nihonbashi Chuo-ku, Tokyo 103-8234, JAPAN
TEL 03-5255-6330
Email yamaguchi.tomohiko.m6@daiichisankyo-hc.co.jp

Public contact
Name of contact person
1st name Yukiyoshi
Middle name
Last name Katsumata
Organization Derma Labo, inc.
Division name headquarter
Zip code 060-0001
Address 2 Kita 1-jo, Nishi 5-chome, Chuo-ku, Sapporo, Hokkaido 060-0001, JAPAN
TEL 011-205-0781
Homepage URL
Email Y.Katsumata@dermalabo.co.jp

Sponsor
Institute Kojinkai, Association of Medical Corporation
Hosui General Medical Clinic.
Institute
Department

Funding Source
Organization DAIICHI SANKYO HEALTHCARE CO., LTD.
R&D Department
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Health Sciences Research Institute, Inc.
Name of secondary funder(s)

IRB Contact (For public release)
Organization Institutional Review Board of Hosui General Medical Clinic
Address 1-4, Nishi 2-chome, Minami 7-jo, Chuou-ku,Sappro 064-0807, Japan
Tel 011-530-0011
Email h.fujita@dermalabo.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions デルマラボ株式会社(北海道)Derma Labo, inc.(Hokkaido prif.)  

Other administrative information
Date of disclosure of the study information
2019 Year 08 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 23
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2018 Year 07 Month 12 Day
Date of IRB
2018 Year 07 Month 26 Day
Anticipated trial start date
2018 Year 08 Month 01 Day
Last follow-up date
2018 Year 11 Month 16 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2018 Year 07 Month 13 Day
Last modified on
2019 Year 09 Month 10 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038003

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.